Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2017 June;59(2) > Panminerva Medica 2017 June;59(2):133-8

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

REVIEW  CONSERVATIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE: HOW TO AVOID OR DEFER DIALYSIS


Panminerva Medica 2017 June;59(2):133-8

DOI: 10.23736/S0031-0808.16.03283-3

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Clinical benefits of phosphate control in progression of end stage renal disease

Piergiorgio BOLASCO, Stefano MURTAS

Territorial Nephrology and Dialysis Unit, ASL Cagliari, Cagliari, Italy


PDF  


It is largely agreed that preservation of residual kidney function (RKF) has a directly proportional affect on general, and in particular cardiovascular, mortality. During evaluation of patients on infrequent hemodialysis (ID) as both as once-weekly or twice-weekly hemodialysis it has been frequently underestimated the importance of phosphaturia, Indeed, the native kidney preserves the ability to eliminate not only toxic molecules but also a significative output of phosphate despite of a severe decrease of RKF. This task the modern membranes are as yet not very efficient of reproducing. The hemodialysis patients on ID who adhere accurately to a low protein diet of 0.6-0.8 g/kg/day could reach a draw in the balance of phosphates. In view of the significant impact produced by poor phosphate control on both RKF and the frequency of even severe cardiovascular effects, infrequent dialysis with its negative or neutral weekly phosphate balance, may constitute a valid “bridging” treatment even in the long-term, thus explaining the improved survival rates compared to patients receiving conventional triweekly hemodialysis.


KEY WORDS: Renal dialysis - Hypophosphatemia, familial - Kidney function tests

top of page

Publication History

Issue published online: February 10, 2017
Article first published online: December 21, 2016

Cite this article as

Bolasco P, Murtas S. Clinical benefits of phosphate control in progression of end stage renal disease. Panminerva Med 2017;59:133-8. DOI: 10.23736/S0031-0808.16.03283-3

Corresponding author e-mail

pg.bolasco@tin.it